Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business Development

NEXT STORY
Skylight Health Announces Closing of Public Offering of 275,000 Shares of Series A Cumulative Redeemable Perpetual Preferred Stock
PREV STORY
Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rexahn Announces $10 Million Registered Direct Offering

ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today ...

author_avatar
NASDAQ Market News

Global Osteoarthritis & Osteoarthritis Pain Market 2019 – There Have Been 40 Licensing & Asset Acquisition Deals Involving Osteoarthritis Drugs During 2013-2018

author_avatar
NASDAQ Market News

NANOBIOTIX Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations

PARIS and CAMBRIDGE, Mass., Oct. 3, 2016 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - ...

author_avatar
NASDAQ Market News